Literature DB >> 21920009

Slipping through the bowel cancer screening programme.

R Hallifax1, M Lacey, P Bevis, N R Borley, T Brooklyn, J M D Wheeler.   

Abstract

AIM: Colorectal cancer is common and a leading cause of cancer death. Faecal occult blood screening has been shown to reduce mortality. The aim of this study was to identify patients in Gloucestershire with a new diagnosis of colorectal cancer who had previously been screened via the Bowel Cancer Screening Programme (BCSP).
METHOD: Between 2006 and 2009, 1030 patients were diagnosed with colorectal cancer. Of these 237 (23%) had been invited to be screened via the BCSP. Their clinical notes were analysed.
RESULTS: Fifty-seven (24%) of the 237 patients had previously had a negative faecal occult blood result. Thirty-three (14%) had their cancer discovered as part of the BCSP. Seventy (30%) had already been diagnosed with colorectal cancer prior to invitation, 62 (26%) did not respond to the invitation, nine (4%) were registered outside Gloucestershire and had therefore not been invited, and three (3%) had died before the invitation. Of the 57 patients with a negative faecal occult blood test, 47 (83%) had colorectal cancer staged Dukes B or C, and 34 (60%) had a rectal or sigmoid cancer.
CONCLUSION: Patients will present with colorectal cancer despite having been invited to participate in the BCSP, with many having received a negative faecal occult blood test. This could be considered a high false negative rate.
© 2011 The Authors. Colorectal Disease © 2011 The Association of Coloproctology of Great Britain and Ireland.

Entities:  

Mesh:

Year:  2012        PMID: 21920009     DOI: 10.1111/j.1463-1318.2011.02828.x

Source DB:  PubMed          Journal:  Colorectal Dis        ISSN: 1462-8910            Impact factor:   3.788


  3 in total

1.  Colorectal cancer screening characteristics of patients presenting with symptoms of colorectal cancer and effect on clinical outcomes.

Authors:  A Saratzis; J Winter-Beatty; C El-Sayed; R Pande; C Harmston
Journal:  Ann R Coll Surg Engl       Date:  2015-07       Impact factor: 1.891

2.  Interval cancers in a population-based screening program for colorectal cancer in catalonia, Spain.

Authors:  M Garcia; X Domènech; C Vidal; E Torné; N Milà; G Binefa; L Benito; V Moreno
Journal:  Gastroenterol Res Pract       Date:  2015-02-24       Impact factor: 2.260

3.  Optimizing the colorectal cancer screening programme using faecal immunochemical test (FIT) in Flanders, Belgium from the "interval cancer" perspective.

Authors:  Thuy Ngan Tran; Marc Peeters; Sarah Hoeck; Guido Van Hal; Sharon Janssens; Harlinde De Schutter
Journal:  Br J Cancer       Date:  2022-01-12       Impact factor: 9.075

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.